Association of FcγRIIIA Polymorphism and THPO Expression With Response to Eltrombopag in Refractory ITP Patients
Association of FC Gamma RIIIA Polymorphism and Thrombopoietin (THPO) Expression With Response to TPO Agonists in Refractory ITP and the Impact of Therapy on B and T Cells Subsets in the Patients With Mutated Genotypes
Sponsor: National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
Listed as NCT02877212, this PHASE3 trial focuses on Immune Thrombocytopenic Purpura (ITP) and remains ongoing. Sponsored by National Institute of Blood and Marrow Transplant (NIBMT), Pakistan, it has been updated 8 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE3
-
Jul 2020 — Jan 2021 [monthly]
Unknown Status PHASE3
-
Sep 2018 — Jul 2020 [monthly]
Unknown Status PHASE3
Status: Recruiting → Unknown Status
▶ Show 3 earlier versions
-
Jun 2018 — Sep 2018 [monthly]
Recruiting PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Jul 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
- Novartis
For direct contact, visit the study record on ClinicalTrials.gov .